Celonic Group
Kristina Ellwanger is currently serving as a Senior Scientific Advisor at Celonic Group since July 2024. Prior to this role, Kristina worked at Affimed from February 2011 to June 2024, where responsibilities included leading a team within Discovery Research and Translational Immunology, developing cutting-edge technologies for protein expression and characterization, and supporting preclinical development. Kristina's earlier experience includes a position as a Postdoc and Senior Scientist at Boehringer Ingelheim from September 2008 to January 2011, focusing on biopharmaceutical process science and cell line development. Kristina began a career in research as a PhD student at the German Cancer Research Center from August 2004 to July 2008, completing a project on Wnt signaling regulators. Educational qualifications include a Dr. rer. nat. from Heidelberg University and a Diploma in Biology from the University of Stuttgart.
This person is not in any offices
Celonic Group
Celonic is a global CDMO (Contract Development & Manufacturing Organization) for innovative biopharmaceuticals and is part of the private and independent family-owned company J.RETTENMAIER & Söhne (JRS Group), with sites in Basel, Switzerland (Headquarters) and Heidelberg, Germany. Celonic provides comprehensive development and manufacturing services for biotherapeutics, including cell line development, USP and DSP development, GMP and non-GMP manufacturing of biopharmaceutical drug substances. Celonic services covered: 2 INDUSTRY LEADING CELL EXPRESSION PLATFORMS: CHOvolution™: - Powered by Celonic's proprietary SEFEX™ technology - Cell line based on CHO-K1 (non-genetically modified CHO) - Cell line adapted to serum-free EMA and FDA compliant media - Simplified licensing model (no royalties from sales) - High productivity (>7 g/l for mABs) GEX®: - Human cells for fully-human glycosylation - Optimized for complex and sophisticated biopharmaceutical products - Stable product quality over full run-time for R&D and/or GMP - High productivity (up to 22g/l bioreactor volume for mAbs ) PROCESS DEVELOPMENT: - State-of-art USP and DSP development - Cutting-edge, in-house, and high throughput bioanalytics - Robust and scalable BIOMANUFACTURING CAPACITIES: - Two facilities (Germany and Basel) - Up to 2,000 L capacity batches in GMP and R&D setup - In-house analytics - Swissmedic GMP certified - 20 years of optimizing perfusion technique with >100 GMP batches NEW BIOLOGICAL ENTITIES : Celonic offers comprehensive approaches to enable clients to achieve commercial success, with a proven track record of developing breakthrough biologics and delivering GMP batches of ex. mABs, Growth Hormones, Fusion Proteins, and Blood Factors. BIOSIMILARS : Celonic offers ready-to-go Biosimilars (cell lines and cell pools—comprehensive analytics methods, comparability data, and development process) shaped on co-development and co-investment of next wave Biosimilars.